Literature DB >> 20411540

Stereodivergent quaternization of 2-alkyl-2-p-tolylsulfinylacetonitriles: NMR spectroscopic evidence of planar and pyramidal benzylic carbanions.

José Luis García Ruano1, Ana M Martín-Castro, Francisco Tato, Esther Torrente, Ana M Poveda.   

Abstract

Enantiomerically enriched alpha,alpha-disubstituted phenylacetonitriles have been readily prepared by stereoselective quaternization of 2-alkyl-2-[2-(p-tolylsulfinyl)phenyl]acetonitriles with different alkylating electrophiles in the presence of bases. The use of potassium hexamethyldisilazane (KHMDS)/[18]crown-6 ether and NHMDS with alkyl halides afforded S,S(S) and R,S(S) diastereoisomers, respectively, in high enantiomeric purities, thus providing stereodivergent processes for synthesizing both isomers. The dependence of the stereochemical course of the reactions on the experimental conditions (mainly on the counterion) has been rationalized by assuming a planar or pyramidal structure for the benzylic carbanions. This hypothesis has been supported by NMR spectroscopic studies, which permit one to assign a chelated pyramidal structure to the sodium benzylic carbanions and an almost planar naked carbanionic structure to the potassium benzylic carbanions generated in the presence of [18]crown-6 ether.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20411540     DOI: 10.1002/chem.200903521

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  Modular, Catalytic Enantioselective Construction of Quaternary Carbon Stereocenters by Sequential Cross-Coupling Reactions.

Authors:  Bowman Potter; Emma K Edelstein; James P Morken
Journal:  Org Lett       Date:  2016-06-16       Impact factor: 6.005

2.  Stereospecific, Nickel-Catalyzed Suzuki-Miyaura Cross-Coupling of Allylic Pivalates To Deliver Quaternary Stereocenters.

Authors:  Kelsey M Cobb; Javon M Rabb-Lynch; Megan E Hoerrner; Alex Manders; Qi Zhou; Mary P Watson
Journal:  Org Lett       Date:  2017-08-07       Impact factor: 6.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.